Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics

Curr Opin Pharmacol. 2017 Feb:32:77-84. doi: 10.1016/j.coph.2016.11.007. Epub 2016 Dec 7.


Opioid chemistry and biology occupy a pivotal place in the history of pharmacology and medicine. Morphine offers unmatched efficacy in alleviating acute pain, but is also associated with a host of adverse side effects. The advent of biased agonism at G protein-coupled receptors has expanded our understanding of intracellular signaling and highlighted the concept that certain ligands are able to differentially modulate downstream pathways. The ability to target one pathway over another has allowed for the development of biased ligands with robust clinical efficacy and fewer adverse events. In this review we summarize these concepts with an emphasis on biased mu opioid receptor pharmacology and highlight how far opioid pharmacology has evolved.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Drug Design
  • Humans
  • Ligands
  • Morphine / adverse effects
  • Morphine / pharmacology
  • Pain / drug therapy*
  • Pain / physiopathology
  • Receptors, Opioid, mu / agonists*
  • Receptors, Opioid, mu / metabolism
  • Signal Transduction / drug effects


  • Analgesics, Opioid
  • Ligands
  • Receptors, Opioid, mu
  • Morphine